




# PHARMACEUTICAL 2019

**INTERCEPT PHARMACEUTICALS  
INC.**  
Rank 286 of 363





# PHARMACEUTICAL 2019

## INTERCEPT PHARMACEUTICALS INC. Rank 286 of 363



The relative strengths and weaknesses of INTERCEPT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTERCEPT PHARMACEUTICALS INC. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 17% points. The greatest weakness of INTERCEPT PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 136% points.

The company's Economic Capital Ratio, given in the ranking table, is -55%, being 92% points below the market average of 37%.

| Input Variable                                 | Value in<br>1000 USD |
|--|----------------------|
| Assets, Current                                | 482,425              |
| Cost of Goods Sold                             | 2,519                |
| Intangible Assets                              | 0                    |
| Liabilities, Current                           | 114,205              |
| Liabilities, Non-Current                       | 375,021              |
| Other Assets                                   | 16,331               |
| Other Compr. Net Income                        | -1,473               |
| Other Expenses                                 | 0                    |
| Other Liabilities                              | 811                  |
| Other Net Income                               | -23,752              |
| Other Revenues                                 | 179,804              |
| Property and Equipment                         | 10,411               |
| Research and Development                       | 207,301              |
| Selling, General and Administrative<br>Expense | 255,474              |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 509,167              |
| Liabilities              | 490,037              |
| Expenses                 | 465,294              |
| Revenues                 | 179,804              |
| Stockholders Equity      | 19,130               |
| Net Income               | -309,242             |
| Comprehensive Net Income | -309,978             |
| Economic Capital Ratio   | -55%                 |